High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer-Reference-Cited by-同舟云学术

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer

Published:2024-06-26 Issue:9 Volume:29 Page:e1231-e1234
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

van Wagensveld Lilian¹²³,Van Nyen Tom⁴⁵,Annibali Daniela⁴⁶,Sonke Gabe S⁷,Kruitwagen Roy F P M³⁸,Amant Frederic⁴⁶⁹,Horlings Hugo M²

Affiliation:

1. Netherlands Comprehensive Cancer Organization (IKNL) Department of Research and Development, , 3511 DT Utrecht , The Netherlands

2. The Netherlands Cancer Institute Department of Molecular Pathology, , 1066 CX Amsterdam , The Netherlands

3. GROW, School for Oncology and Reproduction , 6229 HX Maastricht , The Netherlands

4. KU Leuven and Leuven Cancer Institute (LKI) Gynecological Oncology Laboratory, Department of Oncology, , 3000 Leuven , Belgium

5. The Netherlands Cancer Institute Division of Oncogenomics, , 1066 CX Amsterdam , The Netherlands

6. The Netherlands Cancer Institute Department of Gynaecologic Oncology, , 1066 CX Amsterdam , The Netherlands

7. The Netherlands Cancer Institute Department of Medical Oncology, , 1066 CX Amsterdam , The Netherlands

8. Maastricht University Medical Centre Department of Obstetrics and Gynecology, , 6229 HX Maastricht , The Netherlands

9. University Hospitals Leuven and Department of Oncology Department of Obstetrics and Gynecology, , 3000 Leuven , Belgium

Abstract

Abstract Introduction High-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked to metabolic reprogramming and recurrences in other cancers. Methods Data from 306 patients with advanced-stage HGSOC treated between 2008 and 2015 were analyzed. PHGDH expression levels were determined using immunohistochemistry and categorized as “low” or “high.” Results PHGDH-high was associated with higher FIGO stage and increased use of neoadjuvant chemotherapy. Patients with PHGDH-high tumors had significantly worse survival than PHDH-low, even after adjusting for confounding factors.

Funder

Dutch Cancer Society

Kom Op Tegen Kanker—The Flemish Cancer Society

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/oncolo/article-pdf/29/9/e1231/59036681/oyae161.pdf

Reference7 articles.

1. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Ovarian cancer;Jayson;Lancet,2014

3. On the origin of cancer cells;Warburg;Science,1956

4. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis;Locasale;Nat Genet,2011

5. PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis;Zhang;Cell Rep,2017